Osteosarcoma
Conditions
Interventions
Experimental group:All eligible subjects will receive up to 6 cycles of liposomal doxorubicin plus atezolizumab combination therapy under the guidance of the MDT team. atezolizumab will be maintained
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Osteosarcoma confirmed by histology, with SSS staging of inoperable stage II and metastatic stage III; 2. No other concurrent tumor types; 3. Have received at least first-line systemic treatment in the past and are resistant to drugs; 4. Not previously treated with PD-1 or PD-L1; The cumulative dosage of doxorubicin is =50%; 6. ECOG PS 1-2; 7. Expected lifespan>3 months; 8. 12-60 years old; 9. At least one measurable lesion (RECIST 1.1); 10. Adequate organ function.
Exclusion criteria
Exclusion criteria: 1. Simultaneously suffering from other types of malignant tumors. 2. Cardiac dysfunction or arrhythmia. 3. Uncontrollable complications, such as diabetes. 4. Coagulation disorders. 5. Urinary protein >=++. 6. Chest or peritoneal effusion that requires surgical treatment. 7. Unable to obtain an appropriate amount of tumor tissue through biopsy. 8. Merge other infections or wounds. 9. There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients deemed unsuitable by the researchers to participate in this study. 10. Allergic to anthracycline drugs or experiencing hyperprogression reactions during previous treatment with immune checkpoint inhibitors. 11. Vasodilatory osteosarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;Adverse event; | — |
Countries
China
Contacts
Public ContactYang Qingcheng, Yonggang Wang
Shanghai Sixth People's Hospital
Outcome results
None listed